4-IPP
4-IPP structure
|
Common Name | 4-IPP | ||
|---|---|---|---|---|
| CAS Number | 41270-96-6 | Molecular Weight | 282.08000 | |
| Density | 1.728±0.06 g/cm3 | Boiling Point | 380.2±30.0 °C | |
| Molecular Formula | C10H7IN2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS05, GHS07 |
Signal Word | Danger | |
Use of 4-IPP4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF)[1]. |
| Name | 4-Iodo-6-phenylpyrimidine |
|---|---|
| Synonym | More Synonyms |
| Description | 4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF)[1]. |
|---|---|
| Related Catalog | |
| Target |
MIF[1] |
| In Vitro | 4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity[1]. 4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes[1]. 4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation[1]. 4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner[1]. 4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption [1]. Cell Cytotoxicity Assay[1] Cell Line: BMMs Concentration: 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM Incubation Time: 24 hours, 72 hours Result: Inhibited osteoclastogenesis in a dose-dependent manner. Western Blot Analysis[1] Cell Line: BMMs Concentration: 5 μM,10 μM, 20 μM Incubation Time: 1 day, 3 days, 5 days Result: Inhibited RANKL-induced osteoclast differentiation and bone resorption. |
| In Vivo | 4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation[1]. Animal Model: 8-weeks-old C57BL/6J male mice[1] Dosage: 1 mg/kg, 5 mg/kg Administration: Intraperitoneal injection; every 2 days; for 8 weeks Result: Alleviated OVX-induced osteoporosis. |
| References |
| Density | 1.728±0.06 g/cm3 |
|---|---|
| Boiling Point | 380.2±30.0 °C |
| Molecular Formula | C10H7IN2 |
| Molecular Weight | 282.08000 |
| Exact Mass | 281.96500 |
| PSA | 25.78000 |
| LogP | 2.74820 |
| Storage condition | -20°C |
| Symbol |
GHS05, GHS07 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H302-H315-H318-H335 |
| Precautionary Statements | P261-P280-P305 + P351 + P338 |
| Hazard Codes | C |
| RIDADR | NONH for all modes of transport |
|
Podocyte injury-driven lipid peroxidation accelerates the infiltration of glomerular foam cells in focal segmental glomerulosclerosis.
Am. J. Pathol. 185 , 2118-31, (2015) Intracapillary foam cell infiltration with podocyte alterations is a characteristic pathology of focal segmental glomerulosclerosis (FSGS). We investigated the possible role of podocyte injury in glom... |
|
|
Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer.
BMC Cancer 15 , 843, (2015) Poor prognosis in gallbladder cancer is due to late presentation of the disease, lack of reliable biomarkers for early diagnosis and limited targeted therapies. Early diagnostic markers and novel ther... |
|
|
Macrophage migration inhibitory factor and stearoyl-CoA desaturase 1: potential prognostic markers for soft tissue sarcomas based on bioinformatics analyses.
PLoS ONE 8 , e78250, (2013) The diagnosis and treatment of soft tissue sarcomas (STSs) has been particularly difficult, because STSs are a group of highly heterogeneous tumors in terms of histopathology, histological grade, and ... |
| 4-Jod-2-methyl-6-nitro-anilin |
| iodomethylnitroaniline |
| 4-iodo-2-methyl-6-nitro-aniline |
| 4-iodo-6-phenyl-pyrimidine |
| 4-iodo-2-methyl-6-nitrobenzenamine |
| 4-iodo-6-methyl-2-nitroaniline |
| 5-Jod-3-nitro-2-amino-toluol |